1. Gelteq CEO Nathan Givoni to present at Q4 Investor Summit on December 9. 2. Presentation will cover growth strategy, market positioning, and upcoming catalysts. 3. Event connects investors with microcap companies with compelling value propositions. 4. One-on-one investor meetings scheduled for December 10. 5. Gelteq develops innovative gel-based drug delivery solutions.
FAQ
Why Bullish?
The presentation showcases Gelteq's growth, attracting institutional and HNW investors, which historically boosts stock prices. For instance, prior summits have often led to increased interest in similar companies, enhancing their valuations.
How important is it?
The presentation is likely to draw significant attention to GELS, with a focus on its growth and market opportunities, crucial for its market perception and stock price trajectory.
Why Short Term?
The effect of the summit likely leads to immediate investor interest and potential price movement, similar to past events where companies saw short-term spikes following presentations.
Gelteq Limited to Present at Upcoming Q4 Investor Summit Virtual
MELBOURNE, Australia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (Nasdaq: GELS) announced today that its Chief Executive Officer, Nathan Givoni, will deliver a presentation at the Q4 Investor Summit Virtual on December 9, 2025. In his presentation, Givoni will discuss Gelteq's growth strategy, market positioning, and upcoming catalysts. This event aims to connect investors with innovative small and microcap companies.
Event Details
The Q4 Investor Summit Virtual will showcase MicroCap companies that present compelling value propositions and potential for near-term growth. Givoni is scheduled to present at 4:00 PM ET on December 9, followed by one-on-one meetings with Institutional investors and High Net Worth (HNW) individuals on December 10.
Investors interested in a meeting are encouraged to contact Gelteq's investor relations or the conference contact for details:
- Event: Q4 Investor Summit
- Presentation Date & Time: December 9 | 4:00 PM ET
- Request Access: investorsummitgroup.com
- Conference Contact: fred@investorsummitgroup.com
About Gelteq Limited
Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) focuses on developing and commercializing gel-based oral delivery solutions for various applications including prescription drugs, nutraceuticals, pet care, and sports nutrition. Gelteq's proprietary formulation technology is designed to overcome challenges associated with traditional drug delivery methods, such as taste masking and precision dosing.
For more information about Gelteq, visit www.gelteq.com.
Investor Relations Contacts
Matt Kreps from Darrow Associates serves as the investor relations contact for Gelteq. He can be reached at:
Phone: +1-214-597-8200
Email: mkreps@darrowir.com
Forward-Looking Statements
Certain statements within this announcement may constitute “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. These statements are not historical facts and involve risks and uncertainties that may cause actual results to differ materially from those projected. For more information on these risks, please refer to Gelteq's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 20-F filed on November 17, 2025. Gelteq does not undertake any obligation to update forward-looking statements after the date of this announcement.